A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
← catalyst calendarSponsored by MacroGenics (industry) · MGNX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
154actual
Sites
61
Countries
Australia, Belgium, Bulgaria +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-28 | actual | When the study began enrolling |
| Primary completion | 2026-02-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-16 | actual | The whole study's end, after follow-up |
| First posted | 2023-05-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Androgen-Independent Prostatic Cancer
- Androgen-Independent Prostatic Neoplasms
- Prostate Cancer Recurrent
- Androgen-Insensitive Prostatic Cance
- Androgen-Resistant Prostatic Cancer
- Hormone Refractory Prostatic Cancer
- Immunotherapy
- Immune Checkpoint Inhibitor
- Inhibitory Checkpoint Molecule
Interventions
- Biological: lorigerlimab — also filed as MGD019
- Drug: docetaxel — also filed as Taxotere®
- Drug: Prednisone
Primary outcome
what the primary-completion date above is the date OFMedian radiographic progression free survival (rPFS) determined by investigator review.
measured Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years
Permalink · MGNX's whole pipeline · Catalyst calendar · Every registered study · What changed